Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Additional Information (Details)

v3.23.2
Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
USD ($)
PerformanceObligation
Program
Mar. 31, 2020
USD ($)
Jul. 31, 2018
USD ($)
Program
Aug. 31, 2017
Program
Jun. 30, 2023
USD ($)
Installment
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Installment
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
Apr. 30, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Accounts receivable, reserve for credit losses         $ 0   $ 0   $ 0    
Vaxcyte, Inc.                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue         17,500,000   17,500,000   17,500,000    
Nonrefundable, non-creditable upfront payment receivable                 $ 10,000,000    
Shares received | shares                 167,780    
Common stock fair value                 $ 7,500,000    
Additional nonrefundable and noncreditable payment         5,000,000   5,000,000        
Regulatory milestones cash in payment         $ 75,000,000   $ 75,000,000        
Number of installments | Installment         2   2        
Additional milestone payment         $ 60,000,000   $ 60,000,000        
Blackstone Life Sciences                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Upfront payment received             140,000,000        
BMS Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of programs advancing through preclinical development | Program       4              
Deferred revenue         0   0   0    
2018 BMS Master Services Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue         200,000   200,000   3,100,000    
2015 License Agreement | Blackstone Life Sciences | Royalty                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Upfront payment received             $ 140,000,000        
Revenue interest percentage             4.00%        
2018 Merck Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue         0   $ 0   0    
Milestone payment receivable upon initiation of IND enabling toxicology study                     $ 15,000,000
2018 Merck Agreement | Merck Sharp & Dohme Corp                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of target programs | Program     2                
Initial transaction price     $ 60,000,000                
Contingent payment received                 10,000,000    
Milestone payment received                 2,500,000    
Additional milestone payment received                 7,500,000    
Revenue recognition aggregate contingent payments eligible to receive                   $ 500,000,000  
Milestone method revenue recognition description             If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on the worldwide sales of any commercial products that may result from the collaboration.        
First Cytokine-Derivative Program | Merck Sharp & Dohme Corp                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Upfront payment received   $ 5,000,000                  
Extended research term   1 year                  
2020 Merck Master Services Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue         0   $ 0   0    
MDA Agreement | EMD Serono                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue         0   0   0    
Supply Agreement | Vaxcyte, Inc.                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Reimbursements expenses accruals         5,400,000   5,400,000   4,800,000    
Reimbursements expenses         900,000 $ 3,800,000 2,800,000 $ 6,200,000      
Astellas License and Collaboration Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue         80,200,000   80,200,000   86,100,000    
Number of target programs | Program 3                    
Upfront payment received             90,000,000        
Transaction price $ 90,000,000                    
Estimated service period 4 years                    
Recognition of up front payment $ 89,100,000         89,100,000   89,100,000      
Upfront payment revenue not recognized             32,300,000        
Nonrefundable, non-creditable upfront payment receivable                 $ 90,000,000    
Number of performance obligations | PerformanceObligation 4                    
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate         $ 422,500,000   $ 422,500,000        
Astellas License and Collaboration Agreement | Future Services on Collaboration Joint Steering Committee ("JSC")                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Recognition of up front payment $ 900,000         $ 900,000   $ 900,000